Argenica Therapeutics is a developing novel neuroprotective therapeutics to reduce brain damage after stroke
Argenica Therapeutics has raised $647K in total funding. The most recent round was Grant. The last funding was announced in June 2025.
Argenica Therapeutics's investors include MTPConnect.
Argenica Therapeutics is headquartered in Nedlands, Australia.
Argenica Therapeutics is a developing novel neuroprotective therapeutics to reduce brain damage after stroke
Argenica Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Argenica Therapeutics — Funding & Investors." VCBacked, June 20, 2025, https://www.vcbacked.co/company/argenica-therapeutics. Accessed October 10, 2026.
VCBacked. (2025). Argenica Therapeutics — Funding & Investors. Retrieved October 10, 2026, from https://www.vcbacked.co/company/argenica-therapeutics
{{cite web |title=Argenica Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/argenica-therapeutics |website=VCBacked |access-date=October 10, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated